Innovax-ND-IBD

RSS

cell-associated live recombinant turkey herpesvirus expressing the fusion protein of ND virus and the VP2 protein of IBD virus

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Innovax-ND-IBD.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Innovax-ND-IBD.

For practical information about using Innovax-ND-IBD, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 21/09/2017

Authorisation details

Product details
Name
Innovax-ND-IBD
Agency product number
EMEA/V/C/004422
Active substance
cell-associated live recombinant turkey herpesvirus expressing the fusion protein of ND virus and the VP2 protein of IBD viru,
International non-proprietary name (INN) or common name
cell-associated live recombinant turkey herpesvirus expressing the fusion protein of ND virus and the VP2 protein of IBD virus
Species
Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01AD
Publication details
Marketing-authorisation holder
Intervet International B.V.
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
22/08/2017
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

Product information

22/08/2017 Innovax-ND-IBD - EMEA/V/C/004422 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

IMMUNOLOGICALS FOR AVES

Therapeutic indication

For active immunisation of one-day-old chicks: - to reduce mortality and clinical signs caused by Newcastle disease (ND) virus, - to prevent mortality and to reduce clinical signs and lesions of Infectious bursal disease (IBD), - to reduce mortality, clinical signs and lesions caused by Mareks disease (MD) virus.

Assessment history

How useful was this page?

Add your rating